ClinicalTrials.gg
CompletedNCT05717920Updated Nov 10, 2026Results posted

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

A Phase 2 interventional study of ADX-629 (Open-label) in Atopic Dermatitis, sponsored by Aldeyra Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Aldeyra Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

Updated Nov 10, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
508th of 544
8 · median 96
Started
2023
with 49 others
Phase 2
202 of 639
18 open now
Registered
496th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 508th largest by enrollment of the 544 interventional ones that give a count, is one of 50 that started in 2023, is one of 202 in phase 2, and was the 496th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

A Phase 2, multicenter, adaptive 2-part clinical trial designed to evaluate the safety and efficacy of ADX-629 alone and in combination with standard-of-care in adults with atopic dermatitis.

Read the detailed description

The trial is divided into 2 parts; the first part of the trial (Part 1) is open label, and the second part (Part 2) is randomized, double-blind, and placebo controlled.

In Part 1, approximately 10 subjects will receive open-label ADX-629 twice daily for 90 days.

In Part 2, approximately 40 subjects will be randomized to receive either ADX-629 or matching placebo twice daily for 90 days.

Patients who are interested in participating will be provided detailed information about the study including description of study assessments/procedures, possible side-effects, alternative treatments, and potential benefits.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • eczema
  • atopic
  • adaptive
  • Aldeyra
  • ADX-629
  • Reactive aldehyde species (RASP)
04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥18 years of age
  • History of atopic dermatitis, according to American Academy of Dermatology criteria, that has been present for at least 6 months
  • Mild, moderate, or severe atopic dermatitis, defined as an Investigator Global Assessment (IGA) score of ≥2 at Baseline
  • Not pregnant, breastfeeding, or lactating and agree to use a highly effective method of acceptable for the trial duration, if applicable

Exclusion criteria

Exclusion Criteria:

  • Presence of kidney disease or an estimated (eGFR) of less than or equal to 45 milliliters/min/1.73 m2 during screening
  • History of any unstable chronic diseases/conditions, clinically significant abnormalities, or findings, that in the opinion of the Investigator, could compromise subject safety or affect the conduct of the trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    ADX-629

    Drug: ADX-629 (Open-label)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Serious Adverse Events

    The proportion of subjects that experience at least one serious adverse event

    Time frame: The safety assessment period was approximately 15 weeks.

Secondary outcomes

  1. Proportion of Subjects Achieving ≥ 4 Point Improvement in the Peak Pruritus Numerical Rating Scale

    The Peak Pruritus Numerical Rating Scale is an eleven-point scale (0 = no itch, 10 = worst itch imaginable).

    Time frame: The efficacy assessment period was from Day 1 to Day 90.

  2. Proportion of Subjects With a ≥ 50% Improvement in Eczema Area and Severity Index (EASI) Score at Day 90

    The total EASI score ranges from 0 to 72, with a higher score indicating more severe disease.

    Time frame: The efficacy assessment period was Day 90.

07

Results

Posted Nov 10, 2026

Participant flow

Participant flow — Overall Study
MilestoneADX-629ADX-629 and Topical TherapyADX-629 and Dupilumab
Started521
Completed521
Not completed000

Outcome measures

PrimaryNumber of Subjects With Serious Adverse Events

The proportion of subjects that experience at least one serious adverse event

Time frame:
The safety assessment period was approximately 15 weeks.
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events
ParticipantsADX-629ADX-629 and Topical TherapyADX-629 and Dupilumab
Number of Subjects With Serious Adverse Events000
SecondaryProportion of Subjects Achieving ≥ 4 Point Improvement in the Peak Pruritus Numerical Rating Scale

The Peak Pruritus Numerical Rating Scale is an eleven-point scale (0 = no itch, 10 = worst itch imaginable).

Time frame:
The efficacy assessment period was from Day 1 to Day 90.
Reported as:
Count of participants · Participants
Proportion of Subjects Achieving ≥ 4 Point Improvement in the Peak Pruritus Numerical Rating Scale
ParticipantsADX-629ADX-629 and Topical TherapyADX-629 and Dupilumab
Proportion of Subjects Achieving ≥ 4 Point Improvement in the Peak Pruritus Numerical Rating Scale521
SecondaryProportion of Subjects With a ≥ 50% Improvement in Eczema Area and Severity Index (EASI) Score at Day 90

The total EASI score ranges from 0 to 72, with a higher score indicating more severe disease.

Time frame:
The efficacy assessment period was Day 90.
Reported as:
Count of participants · Participants
Proportion of Subjects With a ≥ 50% Improvement in Eczema Area and Severity Index (EASI) Score at Day 90
ParticipantsADX-629ADX-629 and Topical TherapyADX-629 and Dupilumab
Proportion of Subjects With a ≥ 50% Improvement in Eczema Area and Severity Index (EASI) Score at Day 90400

Adverse events

Collected over The safety assessment period was approximately 15 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ADX-6290/5 (0%)0/5 (0%)4/5 (80%)
ADX-629 and Topical Therapy0/2 (0%)0/2 (0%)0/2 (0%)
ADX-629 and Dupilumab0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventADX-629ADX-629 and Topical TherapyADX-629 and Dupilumab
Groin painMusculoskeletal and connective tissue disorders0/50/21/1
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/50/21/1
MyalgiaMusculoskeletal and connective tissue disorders0/50/21/1
Upper respiratory infectionInfections and infestations2/50/20/1
Urinary tract infectionInfections and infestations1/50/20/1
FlatulenceGeneral disorders1/50/20/1
Tooth fractureInjury, poisoning and procedural complications1/50/20/1
AnxietyPsychiatric disorders1/50/20/1
InsomniaPsychiatric disorders1/50/20/1
Menstrual disorderReproductive system and breast disorders1/50/20/1

Baseline characteristics

Safety population

Age, Continuous
Age, Continuous(years)ADX-629ADX-629 and Topical TherapyADX-629 and DupilumabTotal
Mean40.2 ± 18.0244.0 ± 8.4930.0 ± NA39.9 ± 14.65
Sex: Female, Male
Sex: Female, Male(Participants)ADX-629ADX-629 and Topical TherapyADX-629 and DupilumabTotal
Female4105
Male1113
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ADX-629ADX-629 and Topical TherapyADX-629 and DupilumabTotal
Hispanic or Latino0000
Not Hispanic or Latino5218
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ADX-629ADX-629 and Topical TherapyADX-629 and DupilumabTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0101
White5117
More than one race0000
Unknown or Not Reported0000
08

Study locations

1 site
  • Bexley Dermatology Research
    Bexley, Ohio 43209, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Nov 2023, 9 months.

Results were first posted in Nov 2026, 2 years 11 months after primary completion. A results delay was requested in Oct 2024.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 9 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2023
First posted
Feb 8, 2023
StartActual
Feb 15, 2023
Primary completionActual
Nov 21, 2023
CompletionActual
Nov 21, 2023
Results delay requested
Oct 30, 2024
Results first posted
Nov 10, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 10, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedMild, moderate, or severe atopic dermatitis, defined as an Investigator Global Assessment (IGA) score of ≥2 at Baseline
Exclusion criteria
  • EditedPresence of clinically significant kidney disease or an estimated gloverularglomerular filtration rate (eGFR) of less than or equal to 45 milliliters/min/1.73 m2 during screening
Nov 10, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Adverse Event (AE) QueryNow Number of Subjects With Serious Adverse EventsTime frame: From Day 1 to Day 90 → The safety assessment period was approximately 15 weeks.
Nov 10, 2026
Documents
Secondary outcomes
2 added, 1 removed
What changed in the outcomes
  • AddedProportion of Subjects Achieving ≥ 4 Point Improvement in the Peak Pruritus Numerical Rating ScaleTime frame: The efficacy assessment period was from Day 1 to Day 90.
  • AddedProportion of Subjects With a ≥ 50% Improvement in Eczema Area and Severity Index (EASI) Score at Day 90Time frame: The efficacy assessment period was Day 90.
  • RemovedInvestigator Global Assessment (IGA) ScoreTime frame: From Day 1 to Day 90
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Results posted
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedMild, moderate, or severe atopic dermatitis, defined as an Investigator Global Assessment (IGA) score of ≥2 at Baseline
    Exclusion criteria
    • EditedPresence of clinically significant kidney disease or an estimated gloverularglomerular filtration rate (eGFR) of less than or equal to 45 milliliters/min/1.73 m2 during screening
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Adverse Event (AE) QueryNow Number of Subjects With Serious Adverse EventsTime frame: From Day 1 to Day 90 → The safety assessment period was approximately 15 weeks.
    Secondary outcomes 2 added, 1 removed
    What changed in the outcomes
    • AddedProportion of Subjects Achieving ≥ 4 Point Improvement in the Peak Pruritus Numerical Rating ScaleTime frame: The efficacy assessment period was from Day 1 to Day 90.
    • AddedProportion of Subjects With a ≥ 50% Improvement in Eczema Area and Severity Index (EASI) Score at Day 90Time frame: The efficacy assessment period was Day 90.
    • RemovedInvestigator Global Assessment (IGA) ScoreTime frame: From Day 1 to Day 90
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05717920
Responsible party
Sponsor
First posted
Feb 8, 2023
Start date
Feb 15, 2023
Primary completion
Nov 21, 2023
Completion
Nov 21, 2023
Results posted
Nov 10, 2026
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ADX-629

Start the discussion